Alerts will be sent to your verified email
Verify EmailFDC
|
FDC
|
Orchid Pharma
|
Bliss GVS Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Domestic Sales Growth - YoY
|
5.1 % | n/a | n/a |
|
R&D as a % of Total Sales
|
2.22 % | n/a | 2.7 % |
|
Financials
|
|||
|
5 yr Average ROE
|
12.9 % | 4.49 % | 6.83 % |
|
5yr average Equity Multiplier
|
1.57 | 1.61 | 1.3 |
|
5yr Average Asset Turnover Ratio
|
0.55 | 0.5 | 0.62 |
|
5yr Avg Net Profit Margin
|
15.2 % | 0.56 % | 8.7 % |
|
Price to Book
|
2.51 | 3.98 | 4.28 |
|
P/E
|
22.21 | 249.28 | 39.56 |
|
5yr Avg Cash Conversion Cycle
|
-13.89 Days | 52.03 Days | 186.56 Days |
|
Inventory Days
|
61.89 Days | 112.47 Days | 54.35 Days |
|
Days Receivable
|
18.98 Days | 86.58 Days | 189.93 Days |
|
Days Payable
|
89.17 Days | 159.29 Days | 75.78 Days |
|
5yr Average Interest Coverage Ratio
|
90.41 | 3.01 | 14.68 |
|
5yr Avg ROCE
|
13.8 % | 3.08 % | 13.27 % |
|
5yr Avg Operating Profit Margin
|
17.7 % | 11.84 % | 17.03 % |
|
5 yr average Debt to Equity
|
0.0 | 0.37 | 0.11 |
|
5yr CAGR Net Profit
|
-2.41 % | n/a | 4.24 % |
|
5yr Average Return on Assets
|
8.22 % | 1.2 % | 5.31 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
69.66 % | 69.84 % | 35.36 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.16 % | -20.12 % | 0.32 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
-1.8 % | 16.98 % | 0.0 |
|
FDC
|
Orchid Pharma
|
Bliss GVS Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
-
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|